Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cellsJournal of clinical oncology, 2015-05, Vol.33 (14), p.1543-1550 [Peer Reviewed Journal]Published by the American Society of Clinical Oncology. ;Published by the American Society of Clinical Oncology 2015 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2014.58.9093 ;PMID: 25823737Full text available |
|
2 |
Material Type: Article
|
HPV Vaccination and the Risk of Invasive Cervical CancerThe New England journal of medicine, 2020-10, Vol.383 (14), p.1340-1348 [Peer Reviewed Journal]Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1917338 ;PMID: 32997908Full text available |
|
3 |
Material Type: Article
|
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical CancerThe New England journal of medicine, 2018-11, Vol.379 (20), p.1895-1904 [Peer Reviewed Journal]Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1806395 ;PMID: 30380365Full text available |
|
4 |
Material Type: Article
|
Recognition of RNA N 6 -methyladenosine by IGF2BP proteins enhances mRNA stability and translationNature cell biology, 2018-03, Vol.20 (3), p.285 [Peer Reviewed Journal]EISSN: 1476-4679 ;DOI: 10.1038/s41556-018-0045-z ;PMID: 29476152Full text available |
|
5 |
Material Type: Article
|
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical CancerThe New England journal of medicine, 2021-11, Vol.385 (20), p.1856-1867 [Peer Reviewed Journal]Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2112435 ;PMID: 34534429Full text available |
|
6 |
Material Type: Article
|
MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort studyThe lancet oncology, 2021-04, Vol.22 (4), p.538-547 [Peer Reviewed Journal]2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;COPYRIGHT 2021 Elsevier B.V. ;2021. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30753-1 ;PMID: 33794207Full text available |
|
7 |
Material Type: Article
|
Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical CancerThe New England journal of medicine, 2018-11, Vol.379 (20), p.1905-1914 [Peer Reviewed Journal]Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1804923 ;PMID: 30379613Full text available |
|
8 |
Material Type: Article
|
SUCCOR cone study: conization before radical hysterectomyInternational journal of gynecological cancer, 2022-02, Vol.32 (2), p.117-124 [Peer Reviewed Journal]IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1048-891X ;ISSN: 1525-1438 ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2021-002544 ;PMID: 35039455Full text available |
|
9 |
Material Type: Article
|
Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review StudyJournal of clinical oncology, 2020-04, Vol.38 (10), p.1030-1040 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.19.03012 ;PMID: 32031867Full text available |
|
10 |
Material Type: Article
|
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 TrialJournal of clinical oncology, 2019-11, Vol.37 (31), p.2825-2834 [Peer Reviewed Journal]2019 by American Society of Clinical Oncology 2019 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.19.00739 ;PMID: 31487218Full text available |
|
11 |
Material Type: Article
|
Water-dispersible PEG-curcumin/amine-functionalized covalent organic framework nanocomposites as smart carriers for in vivo drug deliveryNature communications, 2018-07, Vol.9 (1), p.2785-11, Article 2785 [Peer Reviewed Journal]2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2018 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-018-04910-5 ;PMID: 30018290Full text available |
|
12 |
Material Type: Article
|
N 6 -methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modificationCell death & disease, 2020-10, Vol.11 (10), p.911 [Peer Reviewed Journal]EISSN: 2041-4889 ;DOI: 10.1038/s41419-020-03071-y ;PMID: 33099572Full text available |
|
13 |
Material Type: Article
|
Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysisBMJ (Online), 2016-07, Vol.354, p.i3633-i3633 [Peer Reviewed Journal]Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. ;Copyright BMJ Publishing Group LTD Jul 28, 2016 ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to 2016 BMJ ;ISSN: 1756-1833 ;ISSN: 0959-8138 ;EISSN: 1756-1833 ;DOI: 10.1136/bmj.i3633 ;PMID: 27469988Full text available |
|
14 |
Material Type: Article
|
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II TrialJournal of clinical oncology, 2020-12, Vol.38 (34), p.4095-4106 [Peer Reviewed Journal]2020 by American Society of Clinical Oncology 2020 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.20.01920 ;PMID: 33052760Full text available |
|
15 |
Material Type: Article
|
Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505Journal of clinical oncology, 2015-07, Vol.33 (19), p.2129-2135 [Peer Reviewed Journal]2015 by American Society of Clinical Oncology. ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2014.58.4391 ;PMID: 25732161Full text available |
|
16 |
Material Type: Article
|
Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analysesBMJ (Online), 2018-12, Vol.363, p.k4823-k4823 [Peer Reviewed Journal]Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go tohttp://group.bmj.com/group/rights-licensing/permissions2018BMJThis is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:http://creativecommons.org/licenses/by-nc/4.0/. ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to 2018 BMJ ;ISSN: 0959-8138 ;EISSN: 1756-1833 ;DOI: 10.1136/bmj.k4823 ;PMID: 30518635Full text available |
|
17 |
Material Type: Article
|
Human Papillomavirus Infection Determines Prognosis in Cervical CancerJournal of clinical oncology, 2022-05, Vol.40 (14), p.1522-1528 [Peer Reviewed Journal]ISSN: 0732-183X ;ISSN: 1527-7755 ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.21.01930 ;PMID: 35077203Full text available |
|
18 |
Material Type: Article
|
The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical CancerInternational journal of gynecological cancer, 2018-05, Vol.28 (4), p.641-655 [Peer Reviewed Journal]2018 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology. ;2018 2018 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology. ;ISSN: 1048-891X ;ISSN: 1525-1438 ;EISSN: 1525-1438 ;DOI: 10.1097/IGC.0000000000001216 ;PMID: 29688967Full text available |
|
19 |
Material Type: Article
|
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 studyThe lancet oncology, 2021-05, Vol.22 (5), p.609-619 [Peer Reviewed Journal]2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;COPYRIGHT 2021 Elsevier B.V. ;2021. Elsevier Ltd ;ISSN: 1470-2045 ;ISSN: 1474-5488 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00056-5 ;PMID: 33845034Full text available |
|
20 |
Material Type: Article
|
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023International journal of gynecological cancer, 2023-05, Vol.33 (5), p.649-666 [Peer Reviewed Journal]2023 IGCS and ESGO. This is an open access article under the CC BY license. Published by BMJ. ;2023 2023 IGCS and ESGO. This is an open access article under the CC BY license. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023 IGCS and ESGO. This is an open access article under the CC BY license. Published by BMJ. 2023 ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2023-004429 ;PMID: 37127326Full text available |